-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 2021 National Medical Insurance Drug List will be implemented on January 1, 2022
.
The results of the adjustment of the 2021 National Medical Insurance Drug List were announced on December 3.
In this adjustment, a total of 74 drugs were added to the list.
After the adjustment, the total number of drugs in the National Medical Insurance Drug List in 2021 was 2,860
.
At the same time, on December 3, a large number of pharmaceutical companies issued announcements stating that their products were included in the National Medical Insurance Catalog (2021)
.
Zhejiang Medicine: Two drugs are included in the National Medical Insurance Catalogue Zhejiang Medicine Announcement, the company's nanofloxacin malate sodium chloride injection and nanofloxacin malate capsules are newly added or renewed into the "National Medical Insurance Catalogue (2021) "
.
Zejing Pharmaceuticals: Donafinil Toluenesulfonate Tablets will be included in the 2021 National Medical Insurance List
.
The drug is used for patients with unresectable hepatocellular carcinoma who have not received systemic treatment in the past
.
Hengrui Pharmaceuticals: 9 products are included in the National Medical Insurance Program Hengrui Pharmaceuticals announced that 9 of the company's products are included in the National Medical Insurance List
.
Through medical insurance negotiations, Haitrapapax ethanolamine tablets, fluzoparib capsules, remazolam tosylate for injection, and azisartan tablets for injection were included in the national medical insurance catalog for the first time; new indications for apatinib mesylate tablets Included in the national medical insurance catalog; pyrrotinib maleate tablets and thiopefigrastim injection were successfully negotiated for contract renewal and remained in the national medical insurance catalog
.
Glycopyrronium Bromide Injection is directly included in the National Medical Insurance List
.
Bevacizumab injection was adjusted from the "part of the negotiation drug during the agreement period" to the routine national medical insurance list
.
Tibet Pharmaceuticals: Xinhuosu will continue to be included in the National Medical Insurance Drug List.
Tibet Pharmaceuticals issued an announcement.
The National Medical Insurance Bureau and the Ministry of Human Resources and Social Security issued on December 3 the issue of "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drugs" Catalog" (2021), the company's wholly-owned subsidiary Chengdu Nuodikang Biopharmaceutical production of recombinant human brain natriuretic peptide (trade name: Xinhuosu) successfully renewed its contract and was included in the category B scope of the above catalog
.
Xinhuosu medical insurance payment standard: 445 yuan (0.
5mg/bottle), limited to secondary and above medical institutions for short-term treatment of acute decompensated heart failure with poor standard treatment effect, and single hospitalization payment should not exceed 3 days
.
Green Valley (Shanghai) Pharmaceuticals: Negotiations on new Alzheimer's disease drugs entered the medical insurance list.
China's original new drug for the treatment of Alzheimer's disease, Mannite Sodium Capsules (trade name: "Nine Phase One") was included in the list for the first time, and the price was changed from the original price.
Boxes of 895 yuan fell to 296 yuan, a drop of more than 60%
.
After the "Nine Phase One" enters the medical insurance catalogue, based on 4 boxes per month, the patient’s medication costs will be reduced from 3580 yuan to 1184 yuan per month.
To 600 yuan, the cost of direct medication is greatly reduced
.
Hongri Pharmaceuticals: The company's products continue to be included in the National Medical Insurance Drug List.
Hongri Pharmaceuticals announced that the company's product Xuebijing Injection will be renewed under current conditions and continue to be included in the Category B scope of the National Medical Insurance Drug List
.
Haichen Pharmaceuticals: Landiolol Hydrochloride for Injection is included in the National Medical Insurance Catalog Haichen Pharmaceuticals announced that the company's landiolol hydrochloride for injection has been transferred to the National Medical Insurance Catalog for 2021
.
Adrenergic β-receptor blockers are an important cardiovascular therapy drug with a wide range of effects
.
.
The results of the adjustment of the 2021 National Medical Insurance Drug List were announced on December 3.
In this adjustment, a total of 74 drugs were added to the list.
After the adjustment, the total number of drugs in the National Medical Insurance Drug List in 2021 was 2,860
.
At the same time, on December 3, a large number of pharmaceutical companies issued announcements stating that their products were included in the National Medical Insurance Catalog (2021)
.
Zhejiang Medicine: Two drugs are included in the National Medical Insurance Catalogue Zhejiang Medicine Announcement, the company's nanofloxacin malate sodium chloride injection and nanofloxacin malate capsules are newly added or renewed into the "National Medical Insurance Catalogue (2021) "
.
Zejing Pharmaceuticals: Donafinil Toluenesulfonate Tablets will be included in the 2021 National Medical Insurance List
.
The drug is used for patients with unresectable hepatocellular carcinoma who have not received systemic treatment in the past
.
Hengrui Pharmaceuticals: 9 products are included in the National Medical Insurance Program Hengrui Pharmaceuticals announced that 9 of the company's products are included in the National Medical Insurance List
.
Through medical insurance negotiations, Haitrapapax ethanolamine tablets, fluzoparib capsules, remazolam tosylate for injection, and azisartan tablets for injection were included in the national medical insurance catalog for the first time; new indications for apatinib mesylate tablets Included in the national medical insurance catalog; pyrrotinib maleate tablets and thiopefigrastim injection were successfully negotiated for contract renewal and remained in the national medical insurance catalog
.
Glycopyrronium Bromide Injection is directly included in the National Medical Insurance List
.
Bevacizumab injection was adjusted from the "part of the negotiation drug during the agreement period" to the routine national medical insurance list
.
Tibet Pharmaceuticals: Xinhuosu will continue to be included in the National Medical Insurance Drug List.
Tibet Pharmaceuticals issued an announcement.
The National Medical Insurance Bureau and the Ministry of Human Resources and Social Security issued on December 3 the issue of "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drugs" Catalog" (2021), the company's wholly-owned subsidiary Chengdu Nuodikang Biopharmaceutical production of recombinant human brain natriuretic peptide (trade name: Xinhuosu) successfully renewed its contract and was included in the category B scope of the above catalog
.
Xinhuosu medical insurance payment standard: 445 yuan (0.
5mg/bottle), limited to secondary and above medical institutions for short-term treatment of acute decompensated heart failure with poor standard treatment effect, and single hospitalization payment should not exceed 3 days
.
Green Valley (Shanghai) Pharmaceuticals: Negotiations on new Alzheimer's disease drugs entered the medical insurance list.
China's original new drug for the treatment of Alzheimer's disease, Mannite Sodium Capsules (trade name: "Nine Phase One") was included in the list for the first time, and the price was changed from the original price.
Boxes of 895 yuan fell to 296 yuan, a drop of more than 60%
.
After the "Nine Phase One" enters the medical insurance catalogue, based on 4 boxes per month, the patient’s medication costs will be reduced from 3580 yuan to 1184 yuan per month.
To 600 yuan, the cost of direct medication is greatly reduced
.
Hongri Pharmaceuticals: The company's products continue to be included in the National Medical Insurance Drug List.
Hongri Pharmaceuticals announced that the company's product Xuebijing Injection will be renewed under current conditions and continue to be included in the Category B scope of the National Medical Insurance Drug List
.
Haichen Pharmaceuticals: Landiolol Hydrochloride for Injection is included in the National Medical Insurance Catalog Haichen Pharmaceuticals announced that the company's landiolol hydrochloride for injection has been transferred to the National Medical Insurance Catalog for 2021
.
Adrenergic β-receptor blockers are an important cardiovascular therapy drug with a wide range of effects
.
